- Conditions
- Hereditary Angioedema, HAE
- Interventions
- Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331, Dose 4 of BMN 331, Dose 5 of BMN 331, Dose 6 of BMN 331, Dose 7 of BMN 331
- Genetic
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1105–1128
of 10,856
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis, Poliomyelitis
- Interventions
- Polysaccharide Diphtheria Toxoid Conjugate Vaccine
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 4 Years to 7 Years
- Enrollment
- 882 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • Boulder, Colorado • Atlanta, Georgia + 23 more
- Conditions
- Low Back Pain, Spondylosis
- Interventions
- Immediate PT
- Other
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 10 Years to 19 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 5
- States / cities
- Columbus, Ohio • Dublin, Ohio • New Albany, Ohio + 1 more
- Conditions
- Hypochondroplasia
- Interventions
- Not listed
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- Up to 15 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2043
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • Los Angeles, California • Oakland, California + 13 more
- Conditions
- Pediatric Perioperative Blood Pressure Management
- Interventions
- clevidipine
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 2
- States / cities
- Stanford, California • Columbus, Ohio
- Conditions
- Lung Cancer, NSCLC, Non-Small-Cell Lung Cancer
- Interventions
- ABT-751, pemetrexed, placebo
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 27
- States / cities
- Fayetteville, Arkansas • Hot Springs, Arkansas • Greenbrae, California + 23 more
- Conditions
- Clinical Decision Making, Nonarthritic Hip Disease
- Interventions
- Interdisciplinary Evaluation for Nonarthritic Hip Disease, Posture and Movement Training, Treatment-of-choice
- Other
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- PF-02341066, Pemetrexed, Docetaxel
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 119
- States / cities
- Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 58 more
- Conditions
- Lumbar Disc Herniation
- Interventions
- SI-6603, Sham injection
- Drug
- Lead sponsor
- Seikagaku Corporation
- Industry
- Eligibility
- 30 Years to 70 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 67
- States / cities
- Mobile, Alabama • Fountain Valley, California • La Jolla, California + 60 more
- Conditions
- Lung Cancer
- Interventions
- carboplatin, etoposide, paclitaxel, radiation therapy
- Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2007
- U.S. locations
- 86
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Opsumit (macitentan)
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,686 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 144
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Fullerton, California + 117 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- N-acetylcysteine, Placebo
- Drug
- Lead sponsor
- State University of New York - Upstate Medical University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 12
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
- Conditions
- Non-alcoholic Fatty Liver Disease, Liver Cirrhosis
- Interventions
- CC-90001, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 64
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 48 more
- Conditions
- Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenic Purpura, Immune Thrombocytopenia
- Interventions
- Romiplostim, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 25
- States / cities
- Orange, California • San Diego, California • Washington D.C., District of Columbia + 21 more
- Conditions
- Hypercholesterolemia, Mixed Dyslipidemia, Type 2 Diabetes
- Interventions
- Evolocumab, Placebo to Evolocumab
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 424 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 46
- States / cities
- Tuscumbia, Alabama • Phoenix, Arizona • Lomita, California + 39 more
- Conditions
- Cigarette Addiction, Tobacco Use Disorder
- Interventions
- Biospecimen Collection, Questionnaire Administration, Cigarette Purchase Task, Cross-Price Elasticity Task, Daily Diary Surveys, Progressive Ratio Task
- Behavioral
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Progressive Pulmonary Fibrosis
- Interventions
- BMS-986278, BMS-986278 Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 1,057 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 70 more
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- Bevacizumab, Docetaxel, Erlotinib, Pemetrexed
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 485 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 68
- States / cities
- Mobile, Alabama • Glendale, Arizona • Jonesboro, Arkansas + 61 more
- Conditions
- Cigarette Smoking-Related Carcinoma
- Interventions
- Focus Group, Interview, Smoking Cessation Intervention, Survey Administration
- Behavioral · Other
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 14 Years to 24 Years
- Enrollment
- 179 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Sonelokimab, Placebo
- Drug
- Lead sponsor
- MoonLake Immunotherapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 36
- States / cities
- Los Angeles, California • Northridge, California • Sacramento, California + 31 more
- Conditions
- Parkinson's Disease, Levodopa Induced Dyskinesia (LID)
- Interventions
- amantadine HCl ER, Placebo
- Drug
- Lead sponsor
- Adamas Pharmaceuticals, Inc.
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Fountain Valley, California • Irvine, California + 21 more
- Conditions
- Alzheimer's Disease
- Interventions
- Placebo, Idalopirdine
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 933 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 40 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo 0.04 mL twice daily, Placebo 0.04 mL once daily, Placebo 0.08 mL once daily, B - Exenatide 10 mcg twice daily, C - Exenatide 10 mcg once daily, Exenatide 20 mcg once daily
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 23
- States / cities
- La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 19 more
- Conditions
- Tophaceous Gout
- Interventions
- Lesinurad, Placebo, Febuxostat
- Drug
- Lead sponsor
- Ardea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 99
- States / cities
- Birmingham, Alabama • Goodyear, Arizona • Peoria, Arizona + 85 more